Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Modalis Therapeutics Corporation ( (JP:4883) ) has provided an announcement.
Modalis Therapeutics Corporation reported a significant reduction in losses for the fiscal year ending December 31, 2024, compared to the previous year. The improvement in financial results is attributed to a decrease in research and development expenses, indicating a shift in the company’s cost management strategies.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, primarily involved in the biotechnology industry. It focuses on developing therapeutics, leveraging innovations in genetic modulation to address unmet medical needs.
YTD Price Performance: -2.94%
Average Trading Volume: 8,379,093
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen7.2B
See more insights into 4883 stock on TipRanks’ Stock Analysis page.